University of California

The United States of America As Represented by the United States

Lumiphore, Inc.

The United States As Represented by the United States Department of

Kenneth N Raymond

Jide Xu

Stephane Petoud

Seth M Cohen

Frederick L Weitl

Nathaniel G Butlin

Seth D Cohen

David L White

Todd M Corneillie

Eric Werner

Rebecca J Abergel

Evan G Moore

David K Shuh

Daniel M J Doble

Anthony D'Aleo

Christopher J Sunderland

Marlon Thompson

Taylor A Choi

Barry L Engelstad

John P Huberty

Tiffany A Pham

Thomas J McMurry

Thomas M Garrett

Peter W Miller

Robert C Scarrow

Eric J Werner

Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent.

Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

Provided herein are pharmaceutical formularions comprising a 1,2-HOPO chelating agent and/or 3,2-HOPO chelating agent.

The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds comprise hydroxypyridinonyl moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability.

Macrocyclic HOPO chelators

The present invention provides luminescent complexes between a lanthanide ion and an organic ligand which contains 1,2-hydroxypyridinone units. The complexes of the invention are stable in aqueous solutions and are useful as molecular probes, for example in medical diagnostics and bioanalytical assay systems. The invention also provides methods of using the complexes of the invention.

Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides

The invention provides macrocycles useful in chelating metal ions, particularly radionuclides, to provide metal ion complexes. The invention also provides methods of using the compounds and complexes of the invention, such as in therapeutic and diagnostic applications.

Macrocycles

The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands.

Luminescent macrocyclic lanthanide complexes

The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one phthalamidyl moiety. Also provided are probes incorporating the phthalamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention.

Aromatic triamide-lanthanide complexes

The present invention provides hydroxypyridinone and hydroxypyrimidone chelating agents. Also provides are Gd(III) complexes of these agents, which are useful as contrast enhancing agents for magnetic resonance imaging. The invention also provides methods of preparing the compounds of the invention, as well as methods of using the compounds in magnetic resonance imaging applications.

Hydroxypyridonate and hydroxypyrimidinone chelating agents

Phthalamide-lanthanide complexes for use as luminescent markers

The present invention provides luminescent lanthanide metal chelates comprising a metal ion of the lanthanide series and a complexing agent comprising at least one salicylamidyl moiety. Also provided are probes incorporating the salicylamidyl ligands of the invention and methods utilizing the ligands of the invention and probes comprising the ligands of the invention.

Salicylamide-lanthanide complexes for use as luminescent markers

Growing community of inventors

Berkeley, CA, United States of America

Kenneth N Raymond